Rhythm Pharma Q3 IMCIVREE revenue $22.5M, net loss $44.2M; Phase 3 hypothalamic obesity on track

RHYTHM PHARMACEUTICALS, INC.

2023-Q3 EPS reported -$2.50 revenue$53,194,000

Q3 2023 net product revenue from IMCIVREE $22.5M vs $4.3M in Q3 2022; 80% from U.S.
Net loss of $44.2M ($0.76 per share) vs $40.9M loss ($0.79 per share) in Q3 2022.
Phase 3 hypothalamic obesity trial expects full enrollment by end of 2023; 25.5% mean BMI reduction at 1 year in long-term extension (n=12).
Cash & investments $299.3M as of Sep 30, 2023, sufficient to fund operations into 2026.
Company expects 2023 Non-GAAP operating expenses $210M-$220M (R&D $125M-$130M, SG&A $85M-$90M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RHYTHM PHARMACEUTICALS, INC. reported the third quarter ended September 30, 2023 results: revenue $22.5 million.

Period: the third quarter ended September 30, 2023
Revenue: $22.5 million
Result: reported results

Exact text from the filing

Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million

View on SEC.gov

Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-114996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.